¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18
±³À°ÀÏÀÚ : 2021-09-18
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : ¹éÁöÀº
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : kshf4@kshf.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿ø, ÀϹÝÀÇ: 30,000¿ø, Àü°øÀÇ, °£È£»ç, 65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:00~10:30 Optimal HFrEF Treatment, New Perspectives  James Januzzi(Harvard University USA) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:30~11:00 Role of SGLT2I from Chronic to Acute HF, Where Is Proper Position in GDMT?  Michael Bohm(Saarland University Germany) 
Åä·Ð 09-18 ±×·£µåº¼·ë 11:00~11:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 11:20~11:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:30~11:45 Smartphone Application for Cardiac Rehabilitation: Strength and Weakness  ±èÀÀÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:45~12:00 Skeletal Muscle and Prognosis of HF: Can Cardiac Rehabilitation Overcome Muscle Wasting?  Kazunori Shimada(Juntendo University Hospital Japan) 
Åä·Ð 09-18 ±×·£µåº¼·ë 12:00~12:10 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
½Ä»ç 09-18 ±×·£µåº¼·ë 12:10~13:00 Lunch  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:00~13:50 Brigntening Abstract Presentation (II)  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:50~14:10 Challenge of Prescribing Inertia: from CHAMP-HF Registry  Biykem Bozkurt(Baylor College of Medicine HoustonTX) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:10~14:25 Performance Measures for HF Management in Korea  À±Á¾Âù(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:25~14:45 Benefits of Quadruple Therapy for HFrEF  JoAnn Lindenfeld(Vanderbilt University Medical Center Nashville TN) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:45~15:00 Comprehensive or Stepwise Treatment for HFrEF  ÃÖÁ¤Çö(ºÎ»êÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 15:00~15:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 15:20~15:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:20~15:35 Benefit of SGLT2 Inhibitors across the Cardiorenal Continuum  ±ÇÇõ»ó(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:35~15:50 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Non-cardiac effect  ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:50~16:05 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Cardiac Effect  Á¶Àͼº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 16:05~16:20 Positioning of SGLT2 Inhibitors in HF Management: How Should We Sequence?  John McMurray(Univ of Glasgow. UK) 
Åä·Ð 09-18 ±×·£µåº¼·ë 16:20~16:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 16:50~17:00 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:00~17:15 Ischemic Cardiomyopathy  Yuhui Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:15~17:30 Idiopathic Dilated Cardiomyopathy  ÀÌ»ó¾ð(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:30~17:45 Acute and Chronic Myocarditis  Jian Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:45~18:00 Hypertrophic Cardiomyopathy  ±èÀÎö(°è¸íÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 18:00~18:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó)  

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ (¿Â¶óÀÎ) Á¦58Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2021-09-25
´ÙÀ½±Û ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 2ÀÏÂ÷ : 2021-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20470 ´ë±¸ Á¦ 263Â÷ ´ëÇÑ ÇǺΰúÇÐȸ ´ë±¸°æºÏÁöºÎ Áý´ãȸ(¿øÇü Å»¸ð) : 2024-05-02 0 0 2024-04-29
20469 ±¤ÁÖ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ±¤ÁÖÀü³²Áöȸ Á¦51Â÷ ÇмúÁý´ãȸ : 2024-05-02 0 0 2024-04-29
20468 ºÎ»ê ´ëÇÑÀ忬±¸ÇÐȸ ºÎ¿ï°æÁöȸ Á¤±âÁý´ãȸ : 2024-04-29 0 1 2024-04-29
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 80 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 41 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 50 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 38 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 29 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 30 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 30 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 27 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 21 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 39 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 34 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 39 2024-04-17
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷